Li Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Li Zhou has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Zehuai Wen
Guangdong Provincial Hospital of Chinese Medicine (Second Affiliated Hospital of Guangzhou University of Chinese Medicine) Guangdong Provincial Academy of Chinese Medical Sciences Guangzhou China
3 shared publications - Geng Li
The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), the Second Clinical Medical College of Guangzhou University of Chinese Medicine Guangzhou China
2 shared publications - Wenwei Ouyang
Department of Methodology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China
2 shared publications Bo Dong
The Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
1 shared publicationDarong Wu
State Key Laboratory of Dampness Syndrome of Chinese Medicine, Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China
1 shared publicationGuli Jiang
Department of Health Management Center, Guangzhou 11th People’s Hospital, Guangzhou, China
1 shared publication
Latest Publications
- Open Access
- 23 May 2025
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 16, 1518204
Health-related quality of life in populations with diabetes, prediabetes, and normal glycemic levels in Guangzhou, China: a cross-sectional study
Background: The association of prediabetes and diabetes on health-related quality of life (HRQoL) remains inconclusive in current epidemiological research. In this investigation, we administered 5-level EuroQoL-5 dimension version (EQ-5D-5L) to systematically assess HRQoL across glycemic strata (diabetes, prediabetes, and normal glycemic levels) in Guangzhou, and to offer baseline data that can be easily compared to other regions in China or across countries.Method: This investigation utilized baseline cross-sectional data extracted from a three-year prospective cohort study conducted at the Health Management Center of Guangzhou 11th People’s Hospital. Propensity score matching was implemented at a 1:1:4 ratio to balance participants across diabetes, prediabetes, and normal glycemic group. HRQoL outcomes, operationalized through EQ-Index and EQ visual analog scale (EQ-VAS) measurements, were compared across groups using one-way ANOVA or Wilcoxon rank-sum tests. Multivariate linear regression was constructed to adjust for potential confounders, followed by subgroup analyses stratified by sex, age categories, body mass index (BMI) classifications, and hypertension comorbidity status.Results: A total of 18,605 participants were included in the study. After propensity score matching, 533 participants allocated to the prediabetes group, 533 to the diabetes group, and 2064 to the normal glycemic group. Intergroup comparisons demonstrated significantly lower EQ-VAS scores in the diabetes group (79.11) compared to both prediabetes (80.67) and normal glycemic group (81.65). Similarly, the diabetes group exhibited the lowest EQ-Index scores (0.968) relative to prediabetes (0.972) and normal glycemic group (0.972). Multivariate linear regression adjusted with sex, age, BMI, etc. revealed a 2.139-point reduction in EQ-VAS scores for the diabetes group versus normal glycemic group (95% CI: -3.748, -0.530; P=0.009). Subgroup analyses identified particularly compromised HRQoL in diabetes and prediabetes populations among female participants, individuals with obesity, and those aged ≥60 years.Discussion: Prediabetes and diabetes mellitus are associated with diminished HRQoL compared to normal glycemic levels, with a more pronounced negative associations observed among female populations, older adults, and individuals with obesity. These findings emphasize the clinical necessity for implementing targeted interventions to optimize HRQoL outcomes in these high-risk subgroups, which aligns with the fundamental objectives of contemporary diabetes management frameworks.Clinical trial registration: ClinicalTrials.gov ID: NCT05315895.
- 23 May 2025
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 16, 1518204
Open AccessHealth-related quality of life in populations with diabetes, prediabetes, and normal glycemic levels in Guangzhou, China: a cross-sectional study
Background: The association of prediabetes and diabetes on health-related quality of life (HRQoL) remains inconclusive in current epidemiological research. In this investigation, we administered 5-level EuroQoL-5 dimension version (EQ-5D-5L) to systematically assess HRQoL across glycemic strata (diabetes, prediabetes, and normal glycemic levels) in Guangzhou, and to offer baseline data that can be easily compared to other regions in China or across countries.Method: This investigation utilized baseline cross-sectional data extracted from a three-year prospective cohort study conducted at the Health Management Center of Guangzhou 11th People’s Hospital. Propensity score matching was implemented at a 1:1:4 ratio to balance participants across diabetes, prediabetes, and normal glycemic group. HRQoL outcomes, operationalized through EQ-Index and EQ visual analog scale (EQ-VAS) measurements, were compared across groups using one-way ANOVA or Wilcoxon rank-sum tests. Multivariate linear regression was constructed to adjust for potential confounders, followed by subgroup analyses stratified by sex, age categories, body mass index (BMI) classifications, and hypertension comorbidity status.Results: A total of 18,605 participants were included in the study. After propensity score matching, 533 participants allocated to the prediabetes group, 533 to the diabetes group, and 2064 to the normal glycemic group. Intergroup comparisons demonstrated significantly lower EQ-VAS scores in the diabetes group (79.11) compared to both prediabetes (80.67) and normal glycemic group (81.65). Similarly, the diabetes group exhibited the lowest EQ-Index scores (0.968) relative to prediabetes (0.972) and normal glycemic group (0.972). Multivariate linear regression adjusted with sex, age, BMI, etc. revealed a 2.139-point reduction in EQ-VAS scores for the diabetes group versus normal glycemic group (95% CI: -3.748, -0.530; P=0.009). Subgroup analyses identified particularly compromised HRQoL in diabetes and prediabetes populations among female participants, individuals with obesity, and those aged ≥60 years.Discussion: Prediabetes and diabetes mellitus are associated with diminished HRQoL compared to normal glycemic levels, with a more pronounced negative associations observed among female populations, older adults, and individuals with obesity. These findings emphasize the clinical necessity for implementing targeted interventions to optimize HRQoL outcomes in these high-risk subgroups, which aligns with the fundamental objectives of contemporary diabetes management frameworks.Clinical trial registration: ClinicalTrials.gov ID: NCT05315895.
- Open Access
Xuefu Zhuyu Oral Liquid as Adjunctive Therapy on Stable Angina: A Randomized Clinical Trial
Background: Stable angina (SA) is a leading cause of disability worldwide, and there is increasing interest in nonpharmacological treatments. Xuefu Zhuyu oral liquid (XZOL) is a Chinese medicine that has been approved in China for the treatment of SA, but further studies are needed to establish its efficacy and safety. We aimed to provide a reliable assessment of the safety and efficacy of XZOL in patients with SA. Methods: We did a multi-centre, randomised, double-blind, placebo-controlled trial at 6 hospitals in China. Participants were randomized into 2 treatment groups, and allocated to receive of either XZOL or matching placebo over 12 weeks and were followed-up for 12 weeks. The primary efficacy outcome was the average pain intensity of angina, which was measured by the change from baseline to week 12 on a 10-cm visual analogue scale. Results: Of 263 patients screened, 148 participants were randomly assigned with primary outcome data in the ITT (intention-to-treat) population (74 in the XZOL group and 74 in the placebo group), and 99 participants in the PP (per-protocol) population (48 in the XZOL group and 51 in the placebo group). Mean change in VAS at week 12 were −2.27 in the XZOL group and −1.85 in the placebo group (difference - 0.52, 95% CI −0.99 to −0.05; P = 0.029) among the ITT population, and −2.54 in the XZOL group and −1.79 in the placebo group (difference −0.81, 95% CI −1.40 to −0.22; P = 0.007) among the PP population. The neutral results were shown in adjusted and sensitivity analyses. There was no significant difference in adverse events. Conclusion: This randomised, placebo-controlled, double-blind, clinical trial showed XZOL was associated with a significantly greater reduction in the levels of pain intensity of angina over 12 weeks and was superior to placebo in alleviating SA.
Open AccessXuefu Zhuyu Oral Liquid as Adjunctive Therapy on Stable Angina: A Randomized Clinical Trial
Background: Stable angina (SA) is a leading cause of disability worldwide, and there is increasing interest in nonpharmacological treatments. Xuefu Zhuyu oral liquid (XZOL) is a Chinese medicine that has been approved in China for the treatment of SA, but further studies are needed to establish its efficacy and safety. We aimed to provide a reliable assessment of the safety and efficacy of XZOL in patients with SA. Methods: We did a multi-centre, randomised, double-blind, placebo-controlled trial at 6 hospitals in China. Participants were randomized into 2 treatment groups, and allocated to receive of either XZOL or matching placebo over 12 weeks and were followed-up for 12 weeks. The primary efficacy outcome was the average pain intensity of angina, which was measured by the change from baseline to week 12 on a 10-cm visual analogue scale. Results: Of 263 patients screened, 148 participants were randomly assigned with primary outcome data in the ITT (intention-to-treat) population (74 in the XZOL group and 74 in the placebo group), and 99 participants in the PP (per-protocol) population (48 in the XZOL group and 51 in the placebo group). Mean change in VAS at week 12 were −2.27 in the XZOL group and −1.85 in the placebo group (difference - 0.52, 95% CI −0.99 to −0.05; P = 0.029) among the ITT population, and −2.54 in the XZOL group and −1.79 in the placebo group (difference −0.81, 95% CI −1.40 to −0.22; P = 0.007) among the PP population. The neutral results were shown in adjusted and sensitivity analyses. There was no significant difference in adverse events. Conclusion: This randomised, placebo-controlled, double-blind, clinical trial showed XZOL was associated with a significantly greater reduction in the levels of pain intensity of angina over 12 weeks and was superior to placebo in alleviating SA.
- Open Access
- 7 January 2019
- Published by Springer Nature in Trials
- Vol. 20 (1) , 1-7
A core outcome set for clinical trials of Chinese medicine for hyperlipidemia: a study protocol for a systematic review and a Delphi survey
Hyperlipidemia, defined as elevated lipid levels, is the primary and major risk factor for atherosclerotic cardiovascular disease. Several studies have evaluated the effects of Chinese medicine (CM) on hyperlipidemia. However, due to the varied designs and methods of these studies, data synthesis has been difficult, restricting the practical value of the findings. Developing a core outcome set (COS) could solve these methodological concerns. In this paper, we report a protocol to develop a COS for CM clinical trials for hyperlipidemia (COS-CM-Hyperlipidemia). The development of COS-CM-Hyperlipidemia will include four stages: (1) a systematic review to identify potential important outcomes—a study advisory group, composed of core stakeholders of hyperlipidemia, will be set up afterwards to evaluate the identified outcomes and a candidate outcome set will be developed accordingly; (2) a panel of experts will be invited to conduct a three-round Delphi survey, so that the experts’ opinions on the importance of outcomes for treating hyperlipidemia with CM will be collected; (3) a consensus meeting with clinicians, patients, and other key stakeholders will be conducted to finalize the items and definitions; and (4) COS-CM-Hyperlipidemia will be promoted and updated. The development of this COS will improve the design and operation of CM trials on hyperlipidemia, keeping them in compliance with international standards, as well as the comparability and utility of their results. The Core Outcome Measures in Effectiveness Trials Initiative (COMET): http://www.comet-initiative.org/studies/details/983 . Registered on 25 April 2017.
- 7 January 2019
- Published by Springer Nature in Trials
- Vol. 20 (1) , 1-7
Open AccessA core outcome set for clinical trials of Chinese medicine for hyperlipidemia: a study protocol for a systematic review and a Delphi survey
Hyperlipidemia, defined as elevated lipid levels, is the primary and major risk factor for atherosclerotic cardiovascular disease. Several studies have evaluated the effects of Chinese medicine (CM) on hyperlipidemia. However, due to the varied designs and methods of these studies, data synthesis has been difficult, restricting the practical value of the findings. Developing a core outcome set (COS) could solve these methodological concerns. In this paper, we report a protocol to develop a COS for CM clinical trials for hyperlipidemia (COS-CM-Hyperlipidemia). The development of COS-CM-Hyperlipidemia will include four stages: (1) a systematic review to identify potential important outcomes—a study advisory group, composed of core stakeholders of hyperlipidemia, will be set up afterwards to evaluate the identified outcomes and a candidate outcome set will be developed accordingly; (2) a panel of experts will be invited to conduct a three-round Delphi survey, so that the experts’ opinions on the importance of outcomes for treating hyperlipidemia with CM will be collected; (3) a consensus meeting with clinicians, patients, and other key stakeholders will be conducted to finalize the items and definitions; and (4) COS-CM-Hyperlipidemia will be promoted and updated. The development of this COS will improve the design and operation of CM trials on hyperlipidemia, keeping them in compliance with international standards, as well as the comparability and utility of their results. The Core Outcome Measures in Effectiveness Trials Initiative (COMET): http://www.comet-initiative.org/studies/details/983 . Registered on 25 April 2017.